Pharmacogenomics in admixed populations

Trends in Pharmacological Sciences

Volumn 26, Issue 4, 2005, Pages 196-201

  Suarez Kurtz, Guilherme ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CELECOXIB; CHEMOKINE RECEPTOR CCR5; CYCLOOXYGENASE 2; CYTOCHROME P450 2C9; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; MERCAPTOPURINE; MITOCHONDRIAL DNA; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; TENOXICAM; THIOPURINE METHYLTRANSFERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER SUSCEPTIBILITY; DISEASE COURSE; DRUG RESPONSE; ETHNIC GROUP; ETHNOLOGY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENE LOCUS; GENE MAPPING; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEREDITY; HOMOZYGOTE; HUMAN; MEDICAL INFORMATION; PHARMACOGENOMICS; PHENOTYPE; POPULATION GENETICS; POPULATION STRUCTURE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; REVIEW; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SPECIES COMPARISON; WILD TYPE;

EID: 15944428571     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2005.02.008     Document Type: Review

References (65)

1. W. Kalow Pharmacogenetics: Heredity and the response to drugs 1962 W.B. Saunders Philadelphia
2. S.K. Tate, and D.B. Goldstein Will tomorrow's medicines work for everyone? Nat. Genet. 36 Suppl. 2004 S34 S42
3. D.W. Nebert, and A.G. Menon Pharmacogenomic ethnicity and susceptibility genes Pharmacogenomics J. 1 2001 19 22
4. L.L. Cavalli-Sforza The History and Geography of Human Genes 1994 Princeton University Press
5. N. Rosenberg Genetic structure of human populations Science 298 2002 2381 2385
6. R.S. Cooper Race and genomics New Engl. J. Med. 348 2003 1166 1170
7. E.G. Burchard The importance of race and ethnic background in biomedical research and clinical practice New Engl. J. Med. 348 2003 1170 1175
8. M. Bamshad Deconstructing the relationship between genetics and race Nat. Rev. Genet. 5 2004 598 609
9. A. Patrinos Sponsor's foreword: 'Race' and the human genome Nat. Gen. 36 Suppl. 2004 S1 S2
10. S.I. Hamdy Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population Br. J. Clin. Pharmacol. 53 2002 596 603
11. S.I. Hamdy Genotype and allele frequencies of TMPT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population Br. J. Clin. Pharmacol. 55 2002 560 569
12. E. Allillu Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiplicated functional CYP2D6 alleles J. Pharmacol. Exp. Ther. 278 1996 441 446
13. M.G. Scordo Genetic polymorphism of cytochrome CYP2C9 in a Caucasian and a black African population Br. J. Clin. Pharmacol. 52 2001 447 450
14. F. Manny Y-chromosome analysis in Egypt suggests a genetic regional continuity in NorthEastern Africa Hum. Biol. 74 2002 645 658
15. R. Bu Variable drug metabolism genes in Arab population Pharmacogenomics J. 4 2004 260 266
16. J.A. Goldstein Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations Pharmacogenetics 7 1997 59 64
17. W. Tassaneeyakul Analysis of the CYP2C19 polymorphism in a North-eastern Thai population Pharmacogenetics 12 2002 221 225
18. F.M. Salzano, and M.C. Bortolini The Evolution and Genetics of Latin American Populations 2002 Cambridge University Press
19. J. Alves-Silva The ancestry of Brazilian mtDNA lineages Am. J. Hum. Genet. 67 2000 444 461
20. D.R. Carvalho-Silva The phylogeography of Brazilian Y-chromosome lineages Am. J. Hum. Genet. 68 2001 281 286
21. S.M. Callegari-Jacques Historical genetics: Spatiotemporal analysis of the formation of the Brazilian population Am. J. Hum. Biol. 15 2003 824 834
22. F.C. Parra Color and genomic ancestry in Brazilians Proc. Natl. Acad. Sci. U. S. A. 100 2003 177 182
23. st century Hum. Biol. 72 2000 155 177
24. E.J. Parra Estimating African-American admixture proportions by use of population-specific alleles Am. J. Hum. Genet. 63 1998 1839 1851
25. G. Destro-Bisol Estimating European admixture in African Americans by using microsatellites and a microsatellite haplotype (CD4/Alu) Hum. Genet. 104 1999 149 157
26. B. Bertoni Admixture in Hispanics: distribution of ancestral population contributions in the continental United States Hum. Biol. 75 2003 1 11
27. S-J. Lee Race, distributive justice and the promise of pharmacogenomics: ethical considerations Am. J. Pharmacogenomics 3 2003 385 392
28. R. Weinshilboum, and S.L. Sladek Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thipurine methyltransferase activity Am. J. Hum. Genet. 32 1980 651 662
29. H.L. McLeod Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia Leukemia 14 2000 567 572
30. S.A. Coulthard, and L.A. Hogarth Old drugs-current perspectives Curr. Pharmacogen. 2 2004 163 173
31. M. Reis Thiopurine methyltransferase phenotypes and genotypes in Brazilians Pharmacogenetics 13 2003 371 373
32. C. Marzolini Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance Clin. Pharmacol. Ther. 75 2004 13 33
33. M.D. Shriver, and R.A. Kittles Genetic ancestry and the search for personalized genetic histories Nat. Rev. Genet. 5 2004 611 618
34. P.M. McKeigue Mapping genes underlying ethnic differences in disease risk by linkage disequilibrium in recently admixed populations Am. J. Hum. Genet. 60 1997 188 196
35. R.A. Kittles CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum. Genet. 110 2002 553 560
36. R.C.K. Panguluri COX-2 gene promoter haplotypes and prostate cancer risk Carcinogenesis 25 2004 961 966
37. G.M. Vasconcelos CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians Pharmacogenomics J. 5 2005 42 48
38. R.F. Tyndale, and E.M. Sellers Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior Ther. Drug Monit. 24 2002 163 171
39. B.L. Carter A meta-analytic review of the CYP2A6 genotype and smoking behavior Nicotine Tob. Res. 6 2004 221 227
40. K.A. Schoedel Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians Pharmacogenetics 14 2004 615 626
41. E. Gonzalez Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes Proc. Natl. Acad. Sci. U. S. A. 96 1999 12004 12009
42. P.D. Currin The Atlantic Slave Trade: A Census 1969 University of Wisconsin Press
43. S.D. Pena, and M.C. Bortolini Pode a genética definir quem deve se beneficiar das cotas universitárias e demais ações afirmativas? Estudos Avançados 18 2004 31 50
44. L.J. Dickman Identification and functional characterization of a new CYP2Cp variant (CYP2C9*5) expressed among African-Americans Mol. Pharmacol. 60 2001 382 387
45. U. Yasar Analysis of CYP2C9*5 in Caucasian, Oriental and Black-African populations Eur. J. Clin. Pharmacol. 58 2002 555 558
46. A.C. Allabi Genetic polymorphisms of CYP2C9 and CTP2C19 in the Beninese and Belgian populations Br. J. Clin. Pharmacol. 56 2003 653 657
47. A. Llerena Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards Pharmacogenomics J. 4 2004 403 406
48. A.C. Allabi Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11 in vivo among black Africans Clin. Pharmacol. Ther. 76 2004 113 118
49. W.E. Evans, and M.V. Relling Moving towards individualized medicine with pharmacogenomics Nature 429 2004 464 468
50. G. Suarez-Kurtz Pharmacogenomics in admixed population: the Brazilian Pharmacogenetics/pharmacogenomics network - REFARGEN Pharmacogenomics J. 4 2004 347 348
51. R. Vianna-Jorge CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians Clin. Pharmacol. Ther. 76 2004 18 26
52. J. Perini Influence of CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of piroxican Clin. Pharmacol. Ther. 77 2005 P62
53. C. Tang In-vitro metabolism of celecoxib, a ciclooxygenase-2 inhibitor by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics Pharmacogenetics 11 2001 223 235
54. S.S. Brenner Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib Clin. Pharmacokinet. 42 2003 283 292
55. J. Kirchheiner Influence of CYP2C9 on pharmacokinetics of celecoxib and its metabolites Pharmacogenetics 13 2003 473 480
56. C.R. Lee Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1,*1/*2 and*1/*3 genotypes Eur. J. Clin. Pharmacol. 58 2003 791 794
57. J. Kirchheiner Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2 Pharmacogenetics 13 2003 473 480
58. E. Garcia-Martin Individual variability in ibuprofen pharmacokinetics is related to interaction of citochrome P450 2C8 and 2C9 amino acid polymorphisms Clin. Pharmacol. Ther. 76 2004 119 127
59. U. Yasar The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro Eur. J. Clin. Pharmacol. 57 2001 729 735
60. J. Kirchheiner Pharmacokinetic of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans Br. J. Clin. Pharmacol. 55 2003 51 61
61. Special Issue Focus on pharmacogenetics Nat. Rev. Genet. 5 2004 635 680
62. T. Pang Impact of pharmacogenomics on neglected diseases on the developing world Am. J. Pharmacogenomics 3 2003 393 398
63. National Institutes of Health (1994) Guidelines on the inclusion of women and minorities as subjects in clinical research. 59 Fed. Reg. 14508, Mar 28
64. J. Licinio Pharmacogenomics and ethnic minorities Pharmacogenomics J. 1 2001 85
65. H-G. Xie Molecular basis of ethnic differences in drug disposition and response Annu. Rev. Pharmacol. Toxicol. 41 2001 815 850